Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
SRS can effectively control brain metastases in patients with RCC
Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.
Key clinical point: SRS can effectively control brain metastases in patients with RCC, with more than half of treated patients surviving more than a year.
Major finding:. Treated local control rates at 1 and 2 years were 91.8% (95% CI, 85.7-95.4) and 86.1% (77.1-91.7)
Study details: A single-institution study that reviewed the use of SRS to treat brain lesions in 38 patients with a total of 243 brain metastases.
Disclosures: Coauthor James Brugarolas is supported by a grant from the National Institutes of Health. No other study funding was disclosed. The other authors have no disclosures.
Citation:
Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.